FDA Webview
X
about-us-banner

FDA Related News

Home / Articles / FDA Related News
latest-news-card-1
Human Drugs

Orphan Status for Lymphoma Therapy

FDA grants SIRPant Immunotherapeutics an orphan drug designation for SIRPant-M, an autologous macrophage therapy for treating T-cell lymphoma.

latest-news-card-1
Human Drugs

FDA Punts Merck Cough Drug Data to Panel

FDA reviewers say that making an assessment on the clinical meaning of complicated data presentations in a Merck NDA resubmission for chronic cough me...

latest-news-card-1
Human Drugs

FDA Approves CorMedixs Defencath

FDA approves CorMedixs Defencath (taurolidine and heparin) catheter lock solution to reduce catheter-related bloodstream infections in adult patients ...

latest-news-card-1
Human Drugs

Califf Backs Evidence Generation Report

FDA commissioner Robert Califf says the time is right to work on implementing recommendations in a Reagan-Udall Foundation report on post-market evide...

latest-news-card-1
Medical Devices

Baxter Recalls Novum IQ Infusion Pump

Baxter Healthcare recalls its Novum IQ Syringe Infusion Pump because the device may indicate an infusion is complete when it is not.

latest-news-card-1
Human Drugs

Smart Womens Choice Consent Decree

FDA says the Arizona federal court has approved a permanent injunction against Smart Womens Choice and its CEO to prevent them from illegally distribu...

latest-news-card-1
Medical Devices

QS Violations at Ming Fai Industrial

FDA warns Chinas Ming Fai Industrial Co about QS violations in its production of ultrasound gel and probe cover products.

latest-news-card-1
Human Drugs

Insanitary Conditions at Indias Global Pharma

A lengthy FDA Warning Letter details issues at Indias Global Pharma Healthcare that led to contaminated ophthalmic drugs.

latest-news-card-1
Human Drugs

Bayer Withdrawing Aliqopa After Failed Study

Bayer withdraws its NDA for Aliqopa (copanlisib) for adult patients with relapsed follicular lymphoma who have received at least two prior systemic th...

latest-news-card-1
Federal Register

Nonprescription Panel Renewed for 2 Years

Federal Register notice: FDA renews the Nonprescription Drugs Advisory Committee for an additional two years.